Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths

Annals of Diagnostic Pathology

Volumn 14, Issue 6, 2010, Pages 387-395

  Alshenawy, Hanan Alsaeid ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Death rates; E cadherin; EGFR; MMP 9; Ovarian carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; UVOMORULIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER MORTALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; CADHERINS; CARCINOMA; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78349312308     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2010.05.005     Document Type: Article

References (30)

1. Sylvia S., Uwe G., and Ulrich R. Epithelial growth factor receptor status in primary and recurrent ovarian cancer Modern Pathology 19 2006 607 610
2. Bhoola S., and Hoskins W.J. Diagnosis and management of epithelial ovarian cancer Obstet Gynecol 107 2006 1399 1410
3. Crijns A.P., Duiker E.W., De Jong S., Willemse P.H., Van Der Zee A.G., and De Vries E.G. Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy Int J Gynecol Cancer 16 Suppl 1 2006 152 165
4. Qiu L., Di W., and Jiang Q. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death Int J Oncol 27 2005 1441 1448
5. Graeff P.D., Crijns A.P., and ten Hoor K.A. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer Br J Cancer 99 2008 341 349
6. Lo H.W., Hsu S.C., and Hung M.C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization Breast Cancer Res Treat 95 2006 211 218
7. Wang S.C., Nakajima Y., and Yu Y.L. Tyrosine phosphorylation controls PCNA function through protein stability Nat Cell Biol 8 2006 1359 1368
8. Weiya X., Yongkun W., and Yi D. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer Mol Carcinog 48 7 2009 610 617
9. Cowden D.K., Zeineldin R., and Hudson L.G. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells Mol Cancer Res 5 2007 413 421
10. Singh A.P., Senapati S., and Ponnusamy M.P. Clinical potential of mucins in diagnosis, prognosis and therapy of ovarian cancer Lancet Oncol 9 2008 1076 1085
11. Laurie G.H., Natalie M.M., and Sharon S.M. EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma Future Oncol 5 3 2009 323 338
12. Witta S.E., Gemmill R.M., and Hirsch F.R. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines Cancer Res 66 2006 944 950
13. Laura R., Valeriana D.C., and Francesca S. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity Cancer Res 67 2007 6351 6354
14. Overall C.M., and Kleifeld O. Tumour microenvironment: opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nat Rev Cancer 6 2006 227 239
15. Deryugina E.I., and Quigley J.P. Matrix metalloproteinases and tumor metastasis Cancer Metastasis Rev 25 1 2006 9 34
16. Martine P., Isabelle B., and Isabelle H. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer Am J Clin Pathol 129 2008 226 231
17. FIGO Cancer Committee Staging announcement Gynecol Oncol 25 1986 383 385
18. Histological typing of ovarian tumours R.E. Scully, International Histological Classification of Tumours, World Health Organization 2004 Springer Berlin 11 19
19. Han S.W., Hwang P.G., and Chung D.H. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer Int J Cancer 113 2004 109 115
20. Cunningham M.P., Essapen S., and Thomas H. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer Int J Oncol 27 2005 317 325
21. Karen D, Cowden D, Jaime S, et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. Cancer Res 2008; 68, 4606, 4611.
22. Jemal A., Siegel R., and Ward E. Cancer statistics CA Cancer J Clin 56 2006 106 130
23. Lassus H., Sihto H., and Leminen A. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J Mol Med 84 8 2006 671 681
24. Psyrri A., Yu Z., and Weinberger P.M. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis Clin Cancer Res 11 2005 5856 5862
25. Hoshino M., Fukui H., and Ono Y. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma Pathobiology 74 2007 15 21
26. Hudson L.G., Zeineldin R., and Stack M.S. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression Clin Exp Metastasis 9 2008 120 125 Epub
27. Symowicz J., Adley B.P., and Gleason K.J. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells Cancer Res 67 2007 2030 2039
28. Moss N.M., Barbolina M.V., and Liu Y. Ovarian carcinoma cell detachment and multi-cellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in intra-peritoneal metastatic dissemination Cancer Res 69 17 2009 7121 7129
29. Cowden D.K., Symowicz J., and Ning Y. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells Cancer Res 68 2008 4606 4613
30. Belotti D., Calcagno C., and Garofalo A. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion Mol Can Res 6 2008 525 534